Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 9, 2004, Pages 3246-3252

  Sanchez Brunete J A ^a   Dea, M A ^a   Rama, S ^a   Bolas F ^a   Alunda, J M ^b   Raposo, R ^a   Mendez M T ^a   Torrado Santiago, S ^a   Torrado, J J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; MICROSPHERE; PARASITE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG LIVER LEVEL; HAMSTER; HYDROPHILICITY; LETHAL DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SYMPTOMATOLOGY; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; ANTIGENS, PROTOZOAN; ANTIPROTOZOAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; CRICETINAE; DRUG DELIVERY SYSTEMS; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIVER; MALE; MESOCRICETUS; MICROSPHERES; PARTICLE SIZE; SERUM ALBUMIN; SPLEEN;

EID: 4344627254     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.9.3246-3252.2004     Document Type: Article

References (44)

1. Agrawal, A. K., A. Agrawal, A. Pal, P. Y. Guru, and C. M. Gupta. 2002. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J. Drug Target. 10:41-45.
2. Alvar, J., C. Cañavate, B. Gutiérrez-Solar, M. Jiménez, F. Laguna, R. López-Vélez, R. Molina, and J. Moreno. 1997. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev. 10:298-319.
3. Barwicz, J., C. Christian, and I. Gruda. 1992. Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrob. Agents Chemother. 36:2310-2315.
4. Herman, J. D. 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24:684-703.
5. Boswell, G. W., I. Bekersky, D. Buell, R. Hiles, and T. J. Walsh. 1998. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob. Agents Chemother. 42:263-268.
6. Brajtburg, J., S. Elberg, G. S. Kobayashi, and J. Bolard. 1994. Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses. Antimicrob. Agents Chemother. 38:300-306.
7. Cheron, M., C. Petit, J. Bolard, and F. Gaboriau. 2003. Heat-induced reformulation of amphotericin B-deoxycholate favours uptake by the macrophage-like cell line J774. J. Antimicrob Chemother. 52:904-910.
8. Dedet, J. P., and F. Pratlong. 2000. Leishmania, Trypanosoma and monoxenous trypanosomatids as emerging opportunistic agents. J. Eukaryot. Microbiol. 47:37-39.
9. Desjeux, P. 1995. Leishmania/HIV co-infections. Afr. Health 18:20-22.
10. Echevarría, I., C. Barturen, M. J. Renedo, I. F. Trocóniz, and M. C. Dios-Viéitez. 2000. Comparative pharmacokinetics, tissue distribution and effects on renal function of novel polymeric formulations of amphotericin B-deoxycholate in rats. Antimicrob. Agents Chemother. 44:898-904.
11. Espuelas, M. S., P. Legrand, P. M. Loiseau, C. Bories, G. Barrat, and J. M. Irache. 2002. In vitro antileishmanial activity of amphotericin B loaded in poly(epsilon-caprolactone) nanospheres. J. Drug Target. 10:593-599.
12. Falk, R., A. J. Domb, and I. Polacheck. 1999. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob. Agents Chemother. 43:1975-1981.
13. Faries, M. B., I. Bedrosian, C. Reynolds, H. Q. Nguyen, A. Alavi, and B. J. Czerniecki. 2000. Active macromolecule uptake by lymph node antigen-presenting cells: a novel mechanism in determining sentinel lymph node status. Ann. Surg. Oncol. 7:98-105.
14. Gaboriau, F., M. Cheron, C. Petit, and J. Bolard. 1997. Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index. Antimicrob. Agents Chemother. 41:2345-2351.
15. Golenser, J., S. Frankenburg, T. Ehrenfreund, and A. J. Domb. 1999. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob. Agents Chemother. 43:2209-2214.
16. Gradoni, L. 1999. Epizootiology of canine leishmaniasis in southern Europe, p. 32-39. In R. Killick-Kendrick (ed.), Canine leishmaniasis: an update. Hoechst Roussel Vet, Wiesbaden, Germany.
17. Gruda, I., D. Milette, M. Brother, G. S. Kobayashi, G. Medoff, and J. Brajtburg. 1991. Structure-activity study of inhibition of amphotericin B (Fungizone) binding to sterols, toxicity to cells, and lethality to mice by esters of sucrose. Antimicrob. Agents Chemother. 35:24-28.
18. Hill, J. O., R. J. North, and F. M. Collins. 1983. Advantages of measuring changes in the number of viable parasites in murine models of experimental cutaneous leishmaniasis. Infect. Immun. 39:1087-1094.
19. Janknegt, R., S. de Marie, I. A. J. M. Bakker-Woudenberg, and D. J. A. Crommelin. 1992. Liposomal and lipid formulations of amphotericin B. Clin. Pharmacokinet. 23:279-291.
20. Kwong, E. H., M. Ramaswamy, E. A. Bauer, S. C. Hartsel, and K. M. Wasam. 2001. Heat treatment of amphotericin B modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits. Antimicrob. Agents Chemother. 45:2060-2063.
21. Lamothe, J. 2001. Activity of amphotericin B in lipid emulsion in the initial treatment of canine leishmaniasis. J. Small Anim. Pract. 42:170-175.
22. Legrand, P., E. A. Romero, B. E. Cohen, and J. Bolard. 1992. Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob. Agents Chemother. 36:2518-2522.
23. Mauricio, I. L., J. R. Stothard, and M. A. Miles. 2000. The strange case of Leishmania chagasi. Parasitol. Today 16:188-189.
24. Melby, P. C. 2002. Recent developments in leishmaniasis. Curr. Opin. Infect. Dis. 15:485-490.
25. Moreno, M. A., P. Frutos, and M. P. Ballesteros. 2001. Lyophilized lecithin based oil-water microemulsions as a new and low toxic delivery system for amphotericin B. Pharm. Res. 18:344-351.
26. Mullen, A. B., A. J. Baillie, and K. C. Carter. 1998. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibgluconate with those of three proprietary formulations of amphotericin B. Antimicrob. Agents Chemother. 42:2722-2725.
27. Mullen, A. B., K. C. Carter, and A. J. Baillie. 1997. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother. 41:2089-2092.
28. Otsubo, T., S. Maesaki, M. A. Hossain, Y. Yamamoto, K. Tomono, T. Tashiro, J. Seki, Y. Tomii, S. Sonoke, and S. Kohno. 1999. In vitro and in vivo activities of NS718, a new lipid microsphere incorporating amphotericin B, against Aspergillus fumigatus. Antimicrob. Agents Chemother. 43:471-475.
29. Oussoren, C., J. Zuidema, D. J. Crommelin, and G. Storm. 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta 4:261-272.
30. Paul, M., R. Durand, H. Fessi, D. Rivollet, R. Houin, A. Astier, and M. Deniau. 1997. Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Antimicrob. Agents Chemother. 41:1731-1734.
31. Petit, C., M. Cheron, V. Joly, J. M. Rodrigues, J. Bolard, and F. Gaboriau. 1998. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating. J. Antimicrob. Chemother. 42:779-785.
32. Petit, C., V. Yardley, F. Gaboriau, J. Bolard, and S. L. Croft. 1999. Activity of a heat-induced reformulation of amphotericin B deoxycholate (Fungi-zone) against Leishmania donovani. Antimicrob. Agents Chemother. 43:390-392.
33. Proffitt, R. T., A. Satorius, S. M. Chiang, L. Sullivan, and J. P. Adler-Moore. 1991. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AMBisome) in rodents. J. Antimicrob. Chemother. 28(Suppl. B):49-61.
34. Rex, J. H., and T. J. Walsh. 1999. Estimating the true cost of amphotericin B. Clin. Infect. Dis. 29:1408-1410.
35. Santhi, K., S. A. Dhanaraj, S. D. Rajendran, K. Raja, S. Ponnusankar, and B. Suresh. 1999. Nonliposomal approach: a study of preparation of egg albumin nanospheres containing amphotericin B. Drug Dev. Ind. Pharm. 25:547-551.
36. Saxena, S., and P. C. Ghosh. 2000. Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice. Pharm. Res. 17:1236-1242.
37. Souza, L. C., and A. Campa. 1999. Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion. J. Antimicrob. Chemother. 44:77-84.
38. Sundar, S., and M. Rai. 2002. Advances in the treatment of leishmaniasis. Curr. Opin. Infect. Dis. 15:593-598.
39. Titus, R. G., M. Marchand, T. Boon, and J. A. Louis. 1985. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 7:545-555.
40. Torrado, J. J., S. Torrado, J. A. Sánchez-Brunete, F. Bolás, M. A. Dea, S. Rama, and J. M. Alunda. January 2003. Microesferas de anfotericina B. Spanish patent P20030089.
41. Townsed, R. W., A. Zutshi, and I. Bekersky. 2001. Biodistribution of 4-[(14)C]cholesterol-Ambisome following a single intravenous administration to rats. Drug Metab. Dispos. 29:681-685.
42. Urban, R. M., J. J. Jacobs, M. J. Tomlinson, J. Gavrilovic, J. Black, and M. Peoc'h. 2000. Dissemination of wear particles to the liver, spleen, and abdominal nodes of patients with hip or knee replacement. J. Bone Joint Surg. Am. 82:455-456.
43. Wong-Beringer, A., R. A. Jacobs, and B. J. Guglielmo. 1998. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27:603-618.
44. World Health Organization. 4 April 2002, posting date. Leishmaniasis. http://www.who.int/tdr/diseases/leish/files/leish-poster.pdf.